Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385846 | 0.90 | GPR119 (0.51) | GPR119CYP3A4CYP2C19HRH3GPR183 | |
| SCHEMBL390901 | 0.88 | GPR119 (0.63) | GPR119CYP3A4CYP2C19GPR183KCNH2 | |
| SCHEMBL390993 | 0.85 | GPR119 (0.55) | GPR119CYP3A4CYP2C19GPR183KCNH2 | |
| SCHEMBL389546 | 0.85 | GPR119 (0.47) | GPR119CYP3A4CYP2C19HRH3KCNH2 | |
| SCHEMBL13404852 | 0.82 | GPR119 (0.47) | GPR119CYP3A4CYP2C19HRH3AR | |
| SCHEMBL388856 | 0.81 | GPR119 (0.46) | GPR119CYP3A4CYP2C19HRH3AR | |
| SCHEMBL390698 | 0.81 | GPR119 (0.44) | GPR119CYP3A4CYP2C19HRH3AR | |
| SCHEMBL389484 | 0.80 | GPR119 (0.52) | GPR119CYP3A4CYP2C19GPR183KCNH2 | |
| SCHEMBL389924 | 0.79 | HRH3 (0.39) | GPR119CYP3A4CYP2C19HRH3 | |
| SCHEMBL14526640 | 0.78 | GPR119 (0.41) | GPR119CYP3A4CYP2C19HRH3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |